Literature DB >> 29076002

Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme.

Marta Lopes1, Bruno Carvalho2,3, Rui Vaz2,3,4, Paulo Linhares2,3,4.   

Abstract

Neutrophil-lymphocyte ratio (NLR) is a hematological marker of systemic inflammation and several studies demonstrate an association between a higher NLR and a worse prognosis in many malignancies. However, literature analyzing its prognostic value in glioblastoma multiforme (GBM) is still scarce. We intended to analyze the correlation of NLR with overall survival and progression-free survival in patients with GBM performing a retrospective review of the patients with diagnosis of GBM submitted to a resection surgery in the department of neurosurgery of a tertiary care hospital, between January/2005 and January/2013. 140 patients were included. Mean age at surgery was 62.9 ± 10.0 years and mean age at death was 64.4 ± 9.8 years. Mean overall survival was 19.4 ± 14.3 months and mean progression-free survival was 9.4 ± 8.7 months. There was no correlation of NLR, platelets-lymphocyte ratio (PLR) or absolute counts of neutrophils, lymphocytes and platelets with overall survival in multivariate analysis. However, a preoperative NLR ≤ 5 correlated with a shorter progression-free survival [HR 1.56 (SD 95% 1.04-2.34); p = 0.032]. We performed a subgroup analysis of patients who completed Stupp protocol. In this subgroup of 117 patients, a preoperative NLR > 7 correlated with a shorter overall survival [HR 1.65 (SD 95% 1.07-2.53); p = 0.023]. The results from our total cohort didn't confirm the correlation between a higher NRL and worse survival in GBM. However, in the subgroup analysis of patients who completed Stupp protocol, a higher NLR was an independent prognostic factor to a shorter overall survival, similar to existent literature data about GBM.

Entities:  

Keywords:  Epidemiology; Glioblastoma multiforme; Neutrophil–lymphocyte ratio; Overall survival; Progression-free survival

Mesh:

Year:  2017        PMID: 29076002     DOI: 10.1007/s11060-017-2641-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma.

Authors:  George A Alexiou; Evrysthenis Vartholomatos; Spyridon Voulgaris
Journal:  J Neurooncol       Date:  2013-09-15       Impact factor: 4.130

2.  Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Authors:  Amy S Darefsky; Joseph T King; Robert Dubrow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

Review 3.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

4.  Neutrophil infiltration into human gliomas.

Authors:  G Fossati; G Ricevuti; S W Edwards; C Walker; A Dalton; M L Rossi
Journal:  Acta Neuropathol       Date:  1999-10       Impact factor: 17.088

5.  Prognostic factors for glioblastoma patients--a clinical population-based study.

Authors:  B Fekete; K Werlenius; C Örndal; B Rydenhag
Journal:  Acta Neurol Scand       Date:  2015-09-11       Impact factor: 3.209

6.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Authors:  Marc Sanson; Yannick Marie; Sophie Paris; Ahmed Idbaih; Julien Laffaire; François Ducray; Soufiane El Hallani; Blandine Boisselier; Karima Mokhtari; Khe Hoang-Xuan; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

7.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors.

Authors:  V Subeikshanan; A Dutt; D Basu; M N Tejus; V P Maurya; V S Madhugiri
Journal:  J Postgrad Med       Date:  2016 Apr-Jun       Impact factor: 1.476

9.  IDH mutations: genotype-phenotype correlation and prognostic impact.

Authors:  Xiao-Wei Wang; Pietro Ciccarino; Marta Rossetto; Blandine Boisselier; Yannick Marie; Virginie Desestret; Vincent Gleize; Karima Mokhtari; Marc Sanson; Marianne Labussière
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.246

10.  Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.

Authors:  Jun-Rui Chen; Yu Yao; Hong-Zhi Xu; Zhi-Yong Qin
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.817

View more
  27 in total

1.  Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma.

Authors:  Özlem Yersal; Eylem Odabaşi; Özge Özdemir; Yasemin Kemal
Journal:  Mol Clin Oncol       Date:  2018-08-09

2.  Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases.

Authors:  Zhiliang Wang; Liyun Zhong; Guanzhang Li; Ruoyu Huang; Qiangwei Wang; Zheng Wang; Chuanbao Zhang; Baoshi Chen; Tao Jiang; Wei Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

3.  Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.

Authors:  My Le; Ytel Garcilazo; Maria-José Ibáñez-Juliá; Nadia Younan; Louis Royer-Perron; Marion Benazra; Karima Mokhtari; Caroline Houillier; Khê Hoang-Xuan; Agusti Alentorn
Journal:  Oncologist       Date:  2019-03-13

4.  The Role of Preoperative Neutrophil, Platelet, and Monocyte to Lymphocyte Ratios as Independent Prognostic Factors for Patient Survival in WHO 2021 Glioblastoma: A Single-Center Retrospective Study.

Authors:  George S Stoyanov; Emran Lyutfi; Reneta Georgieva; Deyan L Dzhenkov; Lilyana Petkova; Borislav D Ivanov; Ara Kaprelyan; Peter Ghenev
Journal:  Cureus       Date:  2022-06-09

5.  Prognostic significance of preoperative systemic inflammation response index in newly diagnosed glioblastoma patients underwent gross total resection: a propensity score matching analysis.

Authors:  Zhihao Wang; Junhong Li; Yunbo Yuan; Tengfei Li; Mingrong Zuo; Yanhui Liu
Journal:  World J Surg Oncol       Date:  2022-04-29       Impact factor: 3.253

6.  Pretreatment neutrophil-to-lymphocyte ratio plus albumin-to-gamma-glutamyl transferase ratio predict the diagnosis of grade III glioma.

Authors:  Zhen-Qiang He; Hao Duan; Fu-Hua Lin; Ji Zhang; Yin-Sheng Chen; Guan-Hua Zhang; Cheng-Cheng Guo; Chao Ke; Xiang-Heng Zhang; Zheng-He Chen; Jian Wang; Zhong-Ping Chen; Xiao-Bing Jiang; Yong-Gao Mou
Journal:  Ann Transl Med       Date:  2019-11

7.  Development and Validation of a Nomogram Model Based on Hematological Indicators for Predicting the Prognosis of Diffused Gliomas.

Authors:  Song Han; Fang-Wen Qu; Peng-Fei Wang; Ying-Xin Liu; Shou-Wei Li; Chang-Xiang Yan
Journal:  Front Surg       Date:  2022-04-13

8.  Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome.

Authors:  Celine Garrett; Therese M Becker; David Lynch; Joseph Po; Wei Xuan; Kieran F Scott; Paul de Souza
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

9.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

10.  Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma.

Authors:  Puneet Gandhi; Richa Khare; Hanni VasudevGulwani; Sukhpreet Kaur
Journal:  Int J Mol Cell Med       Date:  2018-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.